Lyrica (Pregabalin) Adverse Reactions
Lyrica's most common adverse reactions are dizziness (9-29%), somnolence (5-28%), peripheral edema (2-16%), weight gain (0-12%), dry mouth (1-7%), blurred vision (2-9%), and cognitive impairment ("thinking abnormal" 1-8%), with dose-limiting side effects occurring frequently enough that 14% of patients discontinue treatment compared to 7% on placebo. 1
Most Common Adverse Reactions by Frequency
The FDA label data from controlled trials across all indications demonstrates clear dose-dependent patterns 1:
Central Nervous System Effects (Most Prevalent)
- Dizziness: 9-29% (vs. 5% placebo) - the single most common adverse reaction and leading cause of discontinuation (4% of patients)
- Somnolence: 5-28% (vs. 3% placebo) - second leading cause of discontinuation (4% of patients)
- Ataxia: 4-20% depending on indication
- Cognitive dysfunction ("thinking abnormal"): 1-8% - primarily difficulty with concentration/attention, but also includes cognition, language problems, and slowed thinking
- Confusion: 1-5%
- Incoordination: 2-6%
- Tremor: 1-11%
Metabolic and Physical Effects
- Peripheral edema: 2-16% (vs. 2% placebo) - particularly problematic in diabetic neuropathy patients
- Weight gain: 0-12% (vs. 0-4% placebo) - occurs in approximately 6% of patients overall
- Dry mouth: 1-7% (vs. 1% placebo)
Visual Disturbances
- Blurred vision: 2-9% (vs. 2% placebo)
- Diplopia: 2-9% in epilepsy patients
- Abnormal vision: 1-5%
Serious and Emerging Safety Concerns
Life-Threatening Reactions (Immediate Discontinuation Required)
Angioedema has been reported postmarketing with swelling of face, mouth (tongue, lips, gums), neck (throat and larynx), and life-threatening respiratory compromise 1. Risk is increased in patients taking ACE inhibitors or with prior angioedema history.
Hypersensitivity reactions including skin redness, blisters, hives, rash, dyspnea, and wheezing require immediate discontinuation 1.
Psychiatric and Behavioral Toxicity
Recent pharmacovigilance data reveals concerning patterns 2, 3:
- Misuse and dependence: 3,835 reports (≈1% of total ADRs) including explicit drug abuse (n=42), drug diversion (n=29), substance abuse (n=12), and prescription tampering (n=36)
- Severe psychiatric symptoms: Psychosis, hallucinations, anxiety, depression, euphoria (2-3%), and aggression
- Sexual disinhibition: Particularly in substance-dependent patients
- Functional impairment: Impaired driving ability (n=710), impaired work ability (n=585)
Suicidal behavior and ideation: AEDs including pregabalin double the risk (RR 1.8) compared to placebo, with risk appearing as early as one week and persisting throughout treatment 1.
Rare but Serious Neurological Effects
Myoclonus (both positive and negative) has been reported, even in patients without renal dysfunction, and can present with transient neurological deficits mimicking stroke 4.
Discontinuation Rates and Tolerability
Across all indications, 14% of pregabalin-treated patients discontinued due to adverse reactions versus 7% on placebo 1. The specific discontinuation patterns vary by indication:
- Neuropathic pain (diabetic): 9% discontinuation rate
- Postherpetic neuralgia: 14% discontinuation rate
- Epilepsy (adjunctive): 15% discontinuation rate
- Fibromyalgia: 19% discontinuation rate
The 600 mg/day dose shows significantly higher discontinuation rates than lower doses, while adverse event severity is generally "mild" to "moderate" in 70-90% of patients 1.
Dose-Dependent Patterns
Higher doses (600 mg/day) are associated with greater adverse effect rates but not consistently better efficacy 5. The 300 mg/day dose often provides optimal benefit-to-risk ratio, with 600 mg/day showing increased adverse effects without proportional pain relief improvement 5.
Special Population Considerations
Renal Impairment
Dose reduction is mandatory in renal dysfunction as pregabalin is renally cleared 5. Failure to adjust increases risk of all adverse effects, particularly myoclonus.
Geriatric Patients
Lower starting doses and slower titration are essential 5. Vestibulo-cerebellar effects (ataxia, diplopia, blurred vision) pose significant fall risk.
Drug-Resistant Epilepsy
Ataxia is significantly more common in epilepsy patients compared to other indications 6. Vestibulo-cerebellar adverse events (ataxia, diplopia, blurred vision) occur more frequently in epilepsy, likely reflecting both the underlying condition and polypharmacy with other AEDs.
Critical Clinical Pitfalls
Do not abruptly discontinue: Taper gradually over minimum 1 week to prevent seizure risk in epilepsy patients 1
Screen for substance abuse history: Pregabalin is Schedule V in the US; avoid or monitor intensively in patients with addiction history 5, 2
Monitor for angioedema early: Highest risk during initial treatment and in patients on ACE inhibitors 1
Adjust for renal function: Failure to dose-adjust is a common cause of preventable toxicity
Warn about driving and occupational hazards: Dizziness and somnolence affect 20-40% of patients and impair function 2
Recognize that 70-90% of patients experience some adverse event, though most are mild-moderate 1, 7